Please login to the form below

Not currently logged in
Email:
Password:

Chinese SFDA recalls contaminated Merck vaccine

Officials from the Chinese State Food and Drug Administration recall more than 100,000 vials of Hib child vaccines manufactured by Merck & Co in the country

Officials from the Chinese State Food and Drug Administration (SFDA) have recalled more than 100,000 vials of Hib child vaccines manufactured by Merck & Co in the country.

The Hib vaccines, Pedvaxhib and Comvax, which Merck & Co recalled in an announcement on 12 December, protect against meningitis, pneumonia and other infections. It is administered as a three-dose regimen to children under age five. The first dose is normally given at the age of two months.

Merck & Co said it could not guarantee the sterility of 1.2 million vials made in a Pennsylvania manufacturing facility. Once China officials received the recall notice, they realised that almost 10 per cent of the recalled supplies were in China.

The vaccine has been administered since October 2007. Up to now, no serious adverse effects have been noted. Parents have been warned to check for redness around the administration site as a precaution.

The 1.2 million vials of potentially contaminated vaccines were delivered to eight municipalities and provinces in China, including Beijing.

20th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics